MBOT
Microbot Medical Inc.
Medical - Instruments & Supplies
Market Cap$143M
5Y Perf.-71.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MBOT vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-75.0%
MBOT vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MBOT | NVCR |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $143M | $1.92B |
| Revenue (TTM) | $0.00 | $674M |
| Net Income (TTM) | $-13M | $-173M |
| Gross Margin | — | 75.2% |
| Operating Margin | — | -27.2% |
| Total Debt | $111K | $290M |
| Cash & Equiv. | $3M | $103M |
MBOT vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MBOT
NVCR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Microbot Medical In… (MBOT) | 100 | 28.2 | -71.8% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MBOT vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Microbot Medical Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MBOT
Microbot Medical Inc.
The Income Pick
MBOT is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.85
- EPS growth 30.5%
- Lower volatility, beta 1.85, Low D/E 3.1%, current ratio 2.37x
Best for: income & stability and growth exposure
NVCR
NovoCure Limited
The Long-Run Compounder
NVCR carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 30.3% 10Y total return vs MBOT's -99.4%
- 8.3% revenue growth vs MBOT's -17.1%
- +1.1% vs MBOT's -15.1%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs MBOT's -17.1% |
| Quality / Margins | MBOT | 3.0% margin vs NVCR's -25.7% |
| Stability / Safety | MBOT | Beta 1.85 vs NVCR's 2.20, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.1% vs MBOT's -15.1% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs MBOT's -34.4%, ROIC -16.4% vs -6.2% |
MBOT vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMBOTLAGGINGNVCR
NVCRNovoCure Limited
1leads
MBOTMicrobot Medical Inc.
1leads
6 Total Categories
CATEGORYLEADERvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MBOT1/1
Valuation MetricsMultiples, price ratios, and targets
NVCR2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MBOT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NVCR and MBOT operate at a comparable scale, with $674M and $0 in trailing revenue.
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $0 | $674M |
| EBITDAEarnings before interest/tax | -$14M | -$165M |
| Net IncomeAfter-tax profit | -$13M | -$173M |
| Free Cash FlowCash after capex | -$11M | -$48M |
| Gross MarginGross profit ÷ Revenue | — | +75.2% |
| Operating MarginEBIT ÷ Revenue | — | -27.2% |
| Net MarginNet income ÷ Revenue | — | -25.7% |
| FCF MarginFCF ÷ Revenue | — | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +62.8% | -100.0% |
MBOT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NVCR leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $143M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $140M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.92x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.92x |
| Price / BookPrice ÷ Book value/share | 9.44x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — MBOT and NVCR each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
MBOT delivers a -37.1% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-51 for NVCR. MBOT carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs MBOT's 3/9, reflecting solid financial health.
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | -37.1% | -50.8% |
| ROA (TTM)Return on assets | -34.4% | -16.5% |
| ROICReturn on invested capital | -6.2% | -16.4% |
| ROCEReturn on capital employed | -2.9% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | 0.03x | 0.85x |
| Net DebtTotal debt minus cash | -$3M | $187M |
| Cash & Equiv.Liquid assets | $3M | $103M |
| Total DebtShort + long-term debt | $111,000 | $290M |
| Interest CoverageEBIT ÷ Interest expense | — | -96.80x |
Evenly matched — MBOT and NVCR each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — MBOT and NVCR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MBOT five years ago would be worth $3,030 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs MBOT's -15.1%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | +0.9% | +28.3% |
| 1-Year ReturnPast 12 months | -15.1% | +1.1% |
| 3-Year ReturnCumulative with dividends | +85.2% | -75.7% |
| 5-Year ReturnCumulative with dividends | -69.7% | -91.3% |
| 10-Year ReturnCumulative with dividends | -99.4% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +22.8% | -37.6% |
Evenly matched — MBOT and NVCR each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MBOT and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
MBOT is the less volatile stock with a 1.85 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs MBOT's 45.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.85x | 2.20x |
| 52-Week HighHighest price in past year | $4.67 | $20.06 |
| 52-Week LowLowest price in past year | $1.60 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +45.6% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 46.3 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.5M |
Evenly matched — MBOT and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MBOT as "Buy" and NVCR as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 99.0% for NVCR (target: $34).
| Metric | MBOTMicrobot Medical … | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $5.50 | $33.50 |
| # AnalystsCovering analysts | 3 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MBOT leads in 1 of 6 categories (Income & Cash Flow). NVCR leads in 1 (Valuation Metrics). 3 tied.
Best OverallMicrobot Medical Inc. (MBOT)Leads 1 of 6 categories
Loading custom metrics...
MBOT vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MBOT or NVCR a better buy right now?
Analysts rate Microbot Medical Inc.
(MBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MBOT or NVCR?
Over the past 5 years, Microbot Medical Inc.
(MBOT) delivered a total return of -69. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus MBOT's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MBOT or NVCR?
By beta (market sensitivity over 5 years), Microbot Medical Inc.
(MBOT) is the lower-risk stock at 1. 85β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 19% more volatile than MBOT relative to the S&P 500. On balance sheet safety, Microbot Medical Inc. (MBOT) carries a lower debt/equity ratio of 3% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — MBOT or NVCR?
On earnings-per-share growth, the picture is similar: Microbot Medical Inc.
grew EPS 30. 5% year-over-year, compared to 21. 8% for NovoCure Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MBOT or NVCR?
Microbot Medical Inc.
(MBOT) is the more profitable company, earning 0. 0% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MBOT leads at 0. 0% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MBOT or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MBOT or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Microbot Medical Inc.
(MBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MBOT: -99. 4%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MBOT and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.